126 related articles for article (PubMed ID: 35227457)
1. Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.
Saldarriaga EM; Hauber B; Carlson JJ; Barthold D; Veenstra DL; Devine B
Value Health; 2022 Mar; 25(3):443-450. PubMed ID: 35227457
[TBL] [Abstract][Full Text] [Related]
2. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
3. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
4. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment.
Dhanda DS; Veenstra DL; Regier DA; Basu A; Carlson JJ
J Manag Care Spec Pharm; 2020 Apr; 26(4):529-537. PubMed ID: 32223606
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions.
Roberts MH; Ferguson GT
Pharmacoecon Open; 2021 Mar; 5(1):3-11. PubMed ID: 32557235
[TBL] [Abstract][Full Text] [Related]
7. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
8. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
9. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D
J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280
[No Abstract] [Full Text] [Related]
10. Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method.
Tan S; Wang Y; Tang Y; Jiang R; Chen M; Chen H; Yang F
Front Public Health; 2022; 10():1005453. PubMed ID: 36579068
[TBL] [Abstract][Full Text] [Related]
11. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
12. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
13. A Survey of Payer Perspectives on Cannabis Use Disorder.
Kiselica AM; Duhig A; Montoya I; Skolnick P; Floyd J; Byars C
Subst Use Misuse; 2018 Nov; 53(13):2257-2264. PubMed ID: 29927691
[TBL] [Abstract][Full Text] [Related]
14. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
15. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
[TBL] [Abstract][Full Text] [Related]
16. A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions.
Pearson SD; Dreitlein WB; Towse A; Hampson G; Henshall C
J Comp Eff Res; 2018 Dec; 7(12):1145-1152. PubMed ID: 30427724
[TBL] [Abstract][Full Text] [Related]
17. Attributes Used for Cancer Screening Discrete Choice Experiments: A Systematic Review.
Hall R; Medina-Lara A; Hamilton W; Spencer AE
Patient; 2022 May; 15(3):269-285. PubMed ID: 34671946
[TBL] [Abstract][Full Text] [Related]
18. Examining alignment of community health teams' preferences for health, equity, and spending with state all-payer waiver priorities: A discrete choice experiment.
van den Broek-Altenburg EM; Benson JS; Atherly AJ
Health Serv Res; 2024 Feb; 59 Suppl 1(Suppl 1):e14257. PubMed ID: 37963450
[TBL] [Abstract][Full Text] [Related]
19. Do patients prefer mesh or anterior colporrhaphy for primary correction of anterior vaginal wall prolapse: a labelled discrete choice experiment.
Notten K; Essers BA; Weemhoff M; Rutten A; Donners J; van Gestel I; Kruitwagen R; Roovers J; Dirksen CD
BJOG; 2015 May; 122(6):873-880. PubMed ID: 25041082
[TBL] [Abstract][Full Text] [Related]
20. Patients' preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment.
Geng J; Chen X; Bao H; Qian D; Shao Y; Yu H
BMJ Open; 2020 Sep; 10(9):e038051. PubMed ID: 32967882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
